Search J Rheum

Advanced Search

Home

Current Issue

Archives

Guidelines for Authors

Classified Ads

Links

Search PubMed

Subscriptions

Subscriber Registration

Guidelines for Website Users

JRheum Update Service

Contact Info


Read Full Text


Download PDF


View Table of Contents

Parvovirus B19 May Have a Role in the Pathogenesis of Juvenile Idiopathic Arthritis

BENITO GONZALEZ, CARMEN LARRAÑAGA, OSCAR LEÓN, PATRICIA DÍAZ, MARTA MIRANDA, MARCELO BARRÍA, and ALDO GAGGERO

ABSTRACT.

Objective.
To determine the prevalence of human parvovirus B19 infection in patients with juvenile idiopathic arthritis (JIA) by detection of specific IgM, IgG, and viral DNA.

Methods. Serum samples of 50 patients with diagnosis of JIA and 39 healthy controls were analyzed by ELISA to detect IgG and IgM anti-B19-specific antibodies. The parvovirus B19 genome was detected by nested polymerase chain reaction (PCR). The average age of the patients was 9.6 years (2–14 yrs); 30 were female (60%) and 20 male (40%). The definitive diagnoses of these patients corresponded to 19 systemic forms (38%), 11 to the oligoarticular variety (22%) and 20 to the polyarticular (40%). The average age of the control group was 7.8 years (2–16 yrs); the distribution by sex was 25 females (64%) and 14 males (36%).

Results. IgM against parvovirus B19 was detected in 20% of the cases (10 patients) and B19 DNA genome by PCR in 48% (24 patients); in 10% of the cases (5 patients), both markers were detected. IgG was found in 32% (16 patients). In the control group neither IgM nor the viral genome was detected. However, 43.5% of the controls (17/39) had IgG against parvovirus B19, indicating past infection by the virus.

Conclusion. Our study confirms recent observations regarding a high prevalence of viral DNA in JIA patients and a possible role of this viral infection in JIA pathogenesis. (First Release May 1 2007; J Rheumatol 2007;34:1336-40)

Key Indexing Terms:

PARVOVIRUS B19
JUVENILE IDIOPATHIC ARTHRITIS


From the Immunology Unit, Luis Calvo Mackenna Hospital; Virology Program and Pathophysiology Program, ICBM, Faculty of Medicine, University of Chile; and Rheumatology Unit, San Juan de Dios Hospital, Santiago, Chile.

Supported by Fondecyt grant no. 1030478.

B. González, MD, Immunology Unit, Luis Calvo Mackenna Hospital; C. Larrañaga, MD; O. León, PhD; M. Barría, BSc; A. Gaggero, DVM, Virology Program; P. Díaz, MD, Pathophysiology Program, ICBM, Faculty of Medicine, University of Chile; M. Miranda, MD, Rheumatology Unit, San Juan de Dios Hospital.

Address reprint requests to Dr. A. Gaggero, Virology Program, ICBM, Faculty of Medicine, University of Chile, Independencia 1027, Santiago, Chile. E-mail: agaggero@med.uchile.cl

Accepted for publication February 21, 2007.




Return to June 2007 Table of Contents



© 2007. The Journal of Rheumatology Publishing Company Limited.
All rights reserved.